Get the Stockscreener App
0.4053
2.48%
0.0098
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Vaxart Inc stock is traded at $0.4053, with a volume of 804.47K.
It is up +2.48% in the last 24 hours and up +7.02% over the past month.
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
See More
Previous Close:
$0.3955
Open:
$0.408
24h Volume:
804.47K
Relative Volume:
0.46
Market Cap:
$98.84M
Revenue:
$9.10M
Net Income/Loss:
$-82.47M
P/E Ratio:
-0.6988
EPS:
-0.58
Net Cash Flow:
$-72.32M
1W Performance:
-6.42%
1M Performance:
+7.02%
6M Performance:
-35.47%
1Y Performance:
-49.28%
1-Day Range:
$0.396
$0.413
1-Week Range:
$0.388
$0.4651
52-Week Range:
$0.285
$1.07
Vaxart Inc Stock (VXRT) Company Profile
Name
Vaxart Inc
Sector
Industry
Phone
(650) 550-3500
Address
170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VXRT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VXRT
Vaxart Inc
|
0.4053 | 98.84M | 9.10M | -82.47M | -72.32M | -0.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaxart Inc Stock (VXRT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-24 | Initiated | Oppenheimer | Outperform |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Nov-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-29-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jun-24-21 | Initiated | Jefferies | Buy |
| Jun-11-21 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
View All
Vaxart Inc Stock (VXRT) Latest News
Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025 | VXRT Stock News - GuruFocus
Hagens Berman Sobol Shapiro LLP and Scott+Scott Attorneys at Law LLP Announce a Class Action for All Vaxart Shareholders that May Include You, Even if You Participated in the Previous Partial Settlement with Vaxart - Business Wire
Vaxart Announces Adjournment of Annual Meeting of Stockholders | - GuruFocus
Vaxart Announces Adjournment Of Annual Meeting Of Stockholders - marketscreener.com
Vaxart Announces Adjournment of Annual Meeting of Stockholders | VXRT Stock News - GuruFocus
Vaxart Annual Meeting Adjourned to June 13, 2025; Proxy Advisory Firms Support Proposal No. 2 - Nasdaq
Vaxart Announces Adjournment of Annual Meeting of Stockholders - GlobeNewswire
Vaxart stock climbs on positive study of pill-based norovirus vaccine - MSN
Zoom Rises 8% in 3 Months: Here's Why You Should Buy the Stock Now - The Globe and Mail
Vaxart seeks shareholder nod for reverse stock split By Investing.com - Investing.com South Africa
Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025 - The Manila Times
Vaxart Leaders Set for Key Fireside Chat at Major Healthcare Conference: What to Expect - Stock Titan
Vaxart (VXRT) Releases Video Update Urging Support for Reverse S - GuruFocus
Vaxart seeks shareholder nod for reverse stock split - Investing.com Australia
Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders | VXRT Stock News - GuruFocus
Vaxart’s Founder and Chief Scientific Officer Provides Video Update to Stockholders - GlobeNewswire
Vaxart Founder Makes Urgent Appeal: Critical Nasdaq Compliance Vote Deadline Approaches - Stock Titan
Vaxart Discusses Reverse Stock Split and Capital Raise - TipRanks
Vaxart Answers Additional Frequently Asked Questions from Retail Investors - GlobeNewswire
Vaxart (VXRT) Addresses Stockholder Concerns Ahead of Annual Mee - GuruFocus
Vaxart Begins Phase 2b Trial for Oral COVID-19 Vaccine - TipRanks
Vaxart (VXRT) Addresses Stockholder Concerns Ahead of Annual Meeting | VXRT Stock News - GuruFocus
Vaxart Reveals New Split Ratio Details as Nasdaq Delisting Deadline LoomsCEO Urges Action - Stock Titan
USDJPY Faces An Intraday Corrective Recovery: Elliott Wave Intraday Analysis - The Globe and Mail
Vaxart (VXRT) Advances in Phase 2b Trial with Oral COVID-19 Vacc - GuruFocus
Vaxart Initiates Dosing In 10,000-Participant Portion Of Phase 2B Covid-19 Trial - marketscreener.com
Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial - GlobeNewswire
Vaxart (VXRT) Advances in Phase 2b Trial with Oral COVID-19 Vaccine | VXRT Stock News - GuruFocus
Breakthrough Oral COVID Vaccine Pill Advances: Vaxart Launches Massive 10,000-Patient Trial with $460M Backing - Stock Titan
RFK Jr issues bombshell order on Covid vaccine over safety concerns - MSN
Vaxart (NASDAQ:VXRT) Upgraded at Wall Street Zen - Defense World
Vaxart Urges Stockholder Action: Crucial Nasdaq Compliance Vote Delayed as Reverse Split Hangs in Balance - Stock Titan
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VXRT Stock News - GuruFocus
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vaxart, Inc. Grants Equity Awards to New CFO Jeroen Grasman - Nasdaq
Vaxart Lures New CFO With Massive 1.35M Share Package: Inside the Compensation Deal - Stock Titan
Vaxart Approves Resolutions to Narrow Proposed Reverse - GlobeNewswire
Vaxart seeks approval for reverse stock split to retain Nasdaq listing By Investing.com - Investing.com South Africa
Vaxart Limits Reverse Stock Split To 1-for-20 In Response To Shareholder Feedback - Nasdaq
Vaxart Board Approves Reverse Split Proposal - TipRanks
Vaxart seeks approval for reverse stock split to retain Nasdaq listing - Investing.com Nigeria
Vaxart signals cash runway into Q1 2026 while advancing COVID-19 and norovirus vaccine programs - MSN
Vaxart (VXRT) Eyes Reverse Stock Split to Secure Nasdaq Listing | VXRT Stock News - GuruFocus
Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting | VXRT Stock News - GuruFocus
Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting - The Globe and Mail
Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial - GlobeNewswire
Vaxart gets nod to expand COVID-19 pill vaccine trial By Investing.com - Investing.com South Africa
Vaxart, Inc. Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2B Covid-19 Trial - marketscreener.com
Vaxart (VXRT) Secures BARDA Approval for Next Phase of COVID-19 Vaccine Trial | VXRT Stock News - GuruFocus
Vaxart Receives BARDA Approval for Phase 2b Trial - TipRanks
Vaxart gets nod to expand COVID-19 pill vaccine trial - Investing.com Australia
Vaxart Inc Stock (VXRT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vaxart Inc Stock (VXRT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lo Steven | President, Chief Exec Officer |
May 19 '25 |
Buy |
0.49 |
100,000 |
49,000 |
100,000 |
| Watson W. Mark | Director |
Jun 18 '24 |
Buy |
0.68 |
20,000 |
13,578 |
78,125 |
1.21%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):